Biotech · Private company
Loxo Oncology, Inc.
Track this companyFree. Adds Loxo Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2512 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- AcalabrutinibPhase 3 · Lymphoma, Mantle-CellClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CabozantinibPhase 3 · Medullary Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 3 · Lymphoma, Mantle-CellClinicalTrials.gov · fetched Nov 12, 2026
- IdelalisibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- PirtobrutinibPhase 3 · Lymphoma, Mantle-CellClinicalTrials.gov · fetched Nov 12, 2026
- PirtobrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SelpercatinibPhase 3 · Medullary Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- VandetanibPhase 3 · Medullary Thyroid CancerClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ZanubrutinibPhase 3 · Lymphoma, Mantle-CellClinicalTrials.gov · fetched Nov 12, 2026
- SelpercatinibPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPHASE2 · RECRUITING · started Jan 3, 2025ClinicalTrials.gov NCT06588478 · fetched Nov 12, 2026
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationPHASE2 · RECRUITING · started Jan 22, 2024ClinicalTrials.gov NCT06043674 · fetched Nov 12, 2026
- Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)PHASE2 · RECRUITING · started Dec 20, 2022ClinicalTrials.gov NCT05536349 · fetched Nov 12, 2026
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · RECRUITING · started Jul 22, 2022ClinicalTrials.gov NCT05254743 · fetched Nov 12, 2026
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 20, 2021ClinicalTrials.gov NCT04819100 · fetched Nov 12, 2026
- A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy ParticipantsPHASE1 · COMPLETED · started Dec 3, 2021ClinicalTrials.gov NCT05136404 · fetched Nov 12, 2026
- A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 29, 2021ClinicalTrials.gov NCT05089019 · fetched Nov 12, 2026
- A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 23, 2021ClinicalTrials.gov NCT05023980 · fetched Nov 12, 2026
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 20, 2021ClinicalTrials.gov NCT04965493 · fetched Nov 12, 2026
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 8, 2021ClinicalTrials.gov NCT04662255 · fetched Nov 12, 2026
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 9, 2021ClinicalTrials.gov NCT04666038 · fetched Nov 12, 2026
- A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy ParticipantsPHASE1 · COMPLETED · started Nov 10, 2020ClinicalTrials.gov NCT06165146 · fetched Nov 12, 2026
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 11, 2020ClinicalTrials.gov NCT04211337 · fetched Nov 12, 2026
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 13, 2019ClinicalTrials.gov NCT03899792 · fetched Nov 12, 2026
- A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy ParticipantsPHASE1 · COMPLETED · started Apr 16, 2019ClinicalTrials.gov NCT05630274 · fetched Nov 12, 2026
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLPHASE1_PHASE2 · COMPLETED · started Mar 15, 2019ClinicalTrials.gov NCT03740529 · fetched Nov 12, 2026
- A Study of Selpercatinib (LY3527723) in Healthy ParticipantsPHASE1 · COMPLETED · started Feb 12, 2019ClinicalTrials.gov NCT05338515 · fetched Nov 12, 2026
- A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy ParticipantsPHASE1 · COMPLETED · started Jan 29, 2019ClinicalTrials.gov NCT05469113 · fetched Nov 12, 2026
- A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal FunctionPHASE1 · COMPLETED · started Dec 19, 2018ClinicalTrials.gov NCT05469100 · fetched Nov 12, 2026
- A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy ParticipantsPHASE1 · COMPLETED · started Dec 10, 2018ClinicalTrials.gov NCT05436912 · fetched Nov 12, 2026
- A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male ParticipantsPHASE1 · COMPLETED · started Aug 1, 2018ClinicalTrials.gov NCT05630287 · fetched Nov 12, 2026
- A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy ParticipantsPHASE1 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT05338476 · fetched Nov 12, 2026
- A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy ParticipantsPHASE1 · COMPLETED · started May 31, 2018ClinicalTrials.gov NCT05468164 · fetched Nov 12, 2026
- A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy ParticipantsPHASE1 · COMPLETED · started May 11, 2018ClinicalTrials.gov NCT05338489 · fetched Nov 12, 2026
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 2, 2017ClinicalTrials.gov NCT03157128 · fetched Nov 12, 2026